Gabapentin Tablet
Product Images NDC 71335-3057

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-3057). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clcr (Equation)

This text provides formulas to calculate the Creatinine Clearance (CLCr) based on age, weight, and serum creatinine levels. It includes an adjustment factor for female patients.*

FDA Label Image

Figure-1 (Figure1)

This text provides a figure showing the weekly mean pain scores in the ITT population for Study 1. It includes data points for baseline and weeks 1 to 8. Gabapentin at a dose of 3500 iy is also mentioned in the context of the study.*

FDA Label Image

Figure-2 (Figure2)

FDA Label Image

Figure-3 (Figure3)

This text provides a comparison of responders (patients experiencing over 50% reduction in pain score) in controlled post-herpetic neuralgia (PHN) studies. The chart in Figure 3 shows that study 1 had a 20% response rate while study 2 had a 10% response rate to pain reduction treatment with PBO, GBP 1800, or GBP 2400.*

FDA Label Image

Figure-4 (Figure4)

This text provides a detailed figure showing the responder rate in patients receiving Gabapentin compared to placebo by dose and study. It presents data from adjunctive therapy studies in patients over 12 years of age with partial seizures. The difference in responder rate is expressed as a percentage. The different doses of Gabapentin (600mg, 900mg, 1200mg, and 1800mg) are analyzed in relation to their impact on the responder rate. Study A, Study B, and Study C are likely referenced in the figure, showcasing the effectiveness of Gabapentin in treating partial seizures.*

FDA Label Image

Label (Lbl713353057)

This text describes a medication package insert for Gabapentin tablets containing 800 mg of the active ingredient. It provides instructions on storage conditions, dosage, and usage. The tablets should be kept out of reach of children, stored at 20° to 25°C with permitted excursions to 15° to 30°C, and dispensed in tight, child-resistant containers. The medication is available in a pack of 30 tablets. It also mentions the manufacturer, Bryant Ranch Prepack, Inc., and advises pharmacists to dispense a Medication Guide to each patient.*

FDA Label Image

Struc (Struct)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.